11:52:41 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-11-08 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-20 Ordinarie utdelning IMMU 0.00 SEK
2024-05-17 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-02-14 Bokslutskommuniké 2023
2023-12-13 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-15 Ordinarie utdelning IMMU 0.00 SEK
2023-05-12 Kvartalsrapport 2023-Q1
2023-05-12 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-18 Extra Bolagsstämma 2022
2022-11-11 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-11 Ordinarie utdelning IMMU 0.00 SEK
2022-05-10 Kvartalsrapport 2022-Q1
2022-05-10 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning IMMU 0.00 SEK
2021-05-04 Kvartalsrapport 2021-Q1
2021-05-04 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2021-01-22 Extra Bolagsstämma 2021
2020-12-18 Extra Bolagsstämma 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-04-29 Ordinarie utdelning IMMU 0.00 SEK
2020-04-28 Kvartalsrapport 2020-Q1
2020-04-28 Årsstämma 2020
2020-02-18 Bokslutskommuniké 2019
2019-11-06 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-04-26 Ordinarie utdelning IMMU 0.00 SEK
2019-04-25 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-15 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-17 Kvartalsrapport 2018-Q2
2018-05-04 Kvartalsrapport 2018-Q1
2018-04-26 Ordinarie utdelning IMMU 0.00 SEK
2018-04-25 Årsstämma 2018
2018-02-16 Bokslutskommuniké 2017
2017-12-04 Extra Bolagsstämma 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-19 Kvartalsrapport 2017-Q1
2017-04-27 Ordinarie utdelning IMMU 0.00 SEK
2017-04-26 Årsstämma 2017
2017-02-17 Bokslutskommuniké 2016
2016-05-20 Kvartalsrapport 2016-Q3
2016-02-19 Kvartalsrapport 2016-Q2
2015-12-03 Årsstämma 2016
2015-09-18 Bokslutskommuniké 2015
2015-05-21 Kvartalsrapport 2015-Q3
2015-02-20 Kvartalsrapport 2015-Q2
2014-12-04 Ordinarie utdelning IMMU 0.00 SEK
2014-12-03 Årsstämma 2015
2014-11-18 Kvartalsrapport 2015-Q1
2014-09-17 Bokslutskommuniké 2014
2014-05-07 Kvartalsrapport 2014-Q3
2014-02-18 Kvartalsrapport 2014-Q2
2013-12-04 Ordinarie utdelning IMMU 0.00 SEK
2013-12-03 Kvartalsrapport 2014-Q1
2013-12-03 Årsstämma 2014
2013-09-10 Bokslutskommuniké 2013

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Mendus är verksamt inom medicinteknik. Bolaget producerar terapeutiska vacciner som används inom området för onkologi. Bolaget driver huvudsakligen utveckling inom immunterapi med fokus på behandling av allvarliga tumörer. Exempel på sjukdomar som produkterna används mot innefattar njur- och levercancer. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget gick tidigare under namnet Immunicum och har idag sitt huvudkontor i Stockholm.
2021-01-22 14:00:00

Press Release

22 January 2021

Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021

At the Extraordinary General Meeting (the “EGM”) of Immunicum AB (publ) (IMMU.ST) on 22 January 2021 the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the EGM and the complete proposals, which have previously been published and are available on the company’s website, www.immunicum.com.

Election of Board of Directors and approval of remuneration to the Board
Prior to the EGM, Van Herk Investments B.V. (“Van Herk”) had proposed that the Board would be composed of eight (8) ordinary board members without deputies through election of Dharminder Chahal and Andrea van Elsas as new board members and that current chairman Michael Oredsson and the board members Sven Andreasson, Charlotte Edenius, Steven Glazer, Christine Lind and Helén Tuvesson would remain in the Board.

In light of Michael Oredsson’s resignation from his position as chairman, as well as the Board’s appointment of Christine Lind as interim chairman for the period until the next Annual General Meeting as announced by press release on 21 January 2021, the EGM resolved that the Board shall be composed of seven (7) ordinary board members without deputies. The EGM resolved to elect Dharminder Chahal and Andrea van Elsas as new board members and that Sven Andreasson, Charlotte Edenius, Steven Glazer, Christine Lind and Helén Tuvesson shall remain in the Board for the period until the next Annual General Meeting.

Further, it was resolved in accordance with Van Herk’s proposal that Andrea van Elsas and Dharminder Chahal shall receive the same remuneration as the other board members in the company, i.e., SEK 150,000 on an annual basis. The remuneration shall be adjusted pro rata based on the time from their election as board members up until the Annual General Meeting 2021.

The information in this press release is information that Immunicum AB (publ) is obliged to disclose pursuant to Nasdaq Stockholm’s Rule Book for Issuers. The information was released for public disclosure through the contact person detailed below on 22 January 2021 at 14:00 CET.

For more information, please contact:

Christine Lind, Interim Chairman of the Board of Directors
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com

About Immunicum AB (publ)

Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com